Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

omida ag - artemisia-wermut, d6, 16.666666 %; strychnos mutter-geschwür, d6, 16.666666 %; magnesium phosphoricum, d6, 16.666666 %; artemisia-wermut, d12, 16.666666 %; magnesium phosphoricum, d12, 16.666666 %; strychnos mutter-geschwür, d12, 16.666666 % - tropfen / spray, globuli, tabletten - d - artemisia absinthium, d6, 16.666666 %; strychnos nux-vomica, d6, 16.666666 %; magnesium phosphoricum, d6, 16.666666 %; artemisia absinthium, d12, 16.666666 %; magnesium phosphoricum, d12, 16.666666 %; strychnos nux-vomica, d12, 16.666666 % - homöopathisch

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

allergopharma ag - pollinis allergeni extractum (artemisia vulgaris) - pricktestlösung - pollinis allergeni extractum (artemisia vulgaris) 50000 u., natrii chloridum, glycerolum, phenolum, aqua ad iniectabile ad solutionem pro 1 ml. - diagnostic de l'allergie - allergène: diagnostic

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

allergopharma ag - pollinis allergeni extractum (artemisia vulgaris) - suspension injectable - a): pollinis allergeni extractum (artemisia vulgaris) 1000 u., aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum, natrii hydrogenocarbonas, phenolum, aqua ad iniectabile ad suspensionem pro 1 ml corresp. natrium 3.5 mg. b): pollinis allergeni extractum (artemisia vulgaris) 10000 u., aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum, natrii hydrogenocarbonas, phenolum, aqua ad iniectabile ad suspensionem pro 1 ml corresp. natrium 3.5 mg. - désensibilisation - allergène: agent thérapeutique

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

allergopharma ag - pollinis allergeni extractum (artemisia vulgaris) - suspension injectable - pollinis allergeni extractum (artemisia vulgaris) 10000 u., aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum, natrii hydrogenocarbonas, phenolum, aqua ad iniectabile ad suspensionem pro 1 ml corresp. natrium 3.5 mg. - désensibilisation - allergène: agent thérapeutique

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - des sérums et immunoglobulines, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

altamedics gmbh - nitroprussiate de sodium 60 mg - poudre pour solution pour perfusion - 60 mg - nitroprussiate de sodium dihydraté 60 mg - nitroprusside

Union européenne - français - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belimumab - lupus érythémateux, systémique - immunosuppresseurs - benlysta est indiqué en complément sur le traitement chez les patients âgés de 5 ans et plus active, d'auto-anticorps positifs lupus érythémateux disséminé (sle) avec un haut degré d'activité de la maladie (e. positif anti-adn double brin et complément à faible) malgré le traitement standard. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod de chlorhydrate de - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosuppresseurs - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Canada - français - Health Canada

astrazeneca canada inc - nirsévimab - solution - 50mg - nirsévimab 50mg